Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc: https://mms.businesswire.com/media/20210505005534/en/876086/5/5009664_Horizon_Logo_Full-Color_CMYK_M01_%281%29.jpg
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc
eqs_en 
0 01.12.22
Form 8.3 - The Vanguard Group, Inc.: Amgen Inchttp://commons.wikimedia.org/wiki/File:Amgen.svg: AMGEN INC.
Form 8.3 - The Vanguard Group, Inc.: Amgen Inc
Form 8.3 - The Vanguard Group, Inc.: Amgen Inc
eqs_en 
0 01.12.22
Form 8.3 - The Vanguard Group, Inc.: Amgen Inchttp://commons.wikimedia.org/wiki/File:Amgen.svg: AMGEN INC.
Form 8.3 - The Vanguard Group, Inc.: Amgen Inc
Form 8.3 - The Vanguard Group, Inc.: Amgen Inc
eqs_en 
0 01.12.22
Form 8.3 - The Vanguard Group, Inc.: Amgen Inchttp://commons.wikimedia.org/wiki/File:Amgen.svg: AMGEN INC.
Form 8.3 - The Vanguard Group, Inc.: Amgen Inc
Form 8.3 - The Vanguard Group, Inc.: Amgen Inc
eqs_en 
0 01.12.22
EQS-News: MorphoSys AG: Financial Calendar 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG: Financial Calendar 2023
EQS-News: MorphoSys AG: Financial Calendar 2023
eqs_en 
0 28.11.22
EQS-News: MorphoSys AG: Financial Calendar 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG: Financial Calendar 2023
EQS-News: MorphoSys AG: Financial Calendar 2023
eqs_en 
0 28.11.22
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
eqs_en 
0 16.11.22
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2022 Financial Results
eqs_en 
0 16.11.22
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada: https://mms.businesswire.com/media/20221115005460/en/1637032/5/Canada_office_opening.jpg
Novocure Opens Office in Montreal to Expand and Support Growing Business in Canada


Novocure (NASDAQ: NVCR) today announced it has opened a new office in Montreal to expand and support its growing business in Canada. Novocure is a global oncology company working to extend survival

BusinessWire_EN 
0 15.11.22
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
eqs_en 
0 14.11.22
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-News: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
eqs_en 
0 14.11.22
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
eqs_en 
0 14.11.22
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
EQS-Adhoc: Ad hoc: MorphoSys’ Licensing Partner Roche Provides Update on Phase 3 GRADUATE Program for Gantenerumab in Early Alzheimer’s Disease
eqs_en 
0 14.11.22
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
eqs_en 
0 10.11.22
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
EQS-News: Invitation to MorphoSys’ Third Quarter and First Nine Months 2022 Results Conference Call on November 17, 2022
eqs_en 
0 10.11.22
EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update
EQS-News: Evotec SE reports results for the first nine months 2022 and provides corporate update
eqs_en 
0 09.11.22
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
eqs_en 
0 03.11.22
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
EQS-News: MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
eqs_en 
0 03.11.22
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022
EQS-News: Evotec SE to announce results for the first nine months 2022 on 09 November 2022
eqs_en 
0 03.11.22
EQS-News: Evotec completes acquisition of Central Glass Germany: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec completes acquisition of Central Glass Germany
EQS-News: Evotec completes acquisition of Central Glass Germany
eqs_en 
0 03.11.22
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day
EQS-News: Evotec presents paradigm shift in biologics at Capital Markets Day
eqs_en 
0 02.11.22
EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions
EQS-News: Evotec, CDP Venture Capital and Angelini Ventures launch translational partnership 'Extend' with leading Italian academic Institutions
eqs_en 
0 28.10.22
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
eqs_en 
0 27.10.22
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
EQS-News: MorphoSys Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209) Supporting Its Potential Application in a Broad Array of Advanced Tumors
eqs_en 
0 27.10.22
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis  : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis  
EQS-News: GSK, MorphoSys’ Licensing Partner, Provides Update on ContRAst Phase III Program for Otilimab in Moderate to Severe Rheumatoid Arthritis  
eqs_en 
0 27.10.22